1Hirsch AT,Haskal ZJ,Hertzer NR,et al.ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity,renal,mesenteric,and abdominal aortic):a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery,Society for Cardiovascular Angiography and Interventions,Society for Vascular Medicine and Biology,Society of Interventional Radiology,and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease):endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation;National Heart,Lung,and Blood Institute;Society for Vascular Nursing;TransAtlantic Inter-Society Consensus;and Vascular Disease Foundation[J].Circulation,2006,113(11):463-654.
2The ICAI Study Group.Prostanoids for chronic critical leg ischemia.A rand omized,controlled,open-label trial with prostagland in E1.Ischemia Cronica degli Arti Inferiori[J].Ann Intern Med,1999,130(5):412-421.
3Albers M,Fratezi AC,De Luccia N.Assessment of quality of life of patients with severe ischemia as a result of infrainguinal arterial occlusive disease[J].J Vasc Surg,1992,16(1):54-59.
4Davies N,Dobner S,Bezuidenhout D,et al.The dosage dependence of VEGF stimulation on scaffold neovascularisation[J].Biomaterials,2008,29(26):3531-3538.
5Adams RH,Alitalo K.Molecular regulation of angiogenesis and lymphangiogenesis[J].Nat Rev Mol Cell Biol,2007,8(6):464-478.
6Simons M.Angiogenesis:where do we stand now[J] ? Circulation,2005,111(12):1556-1566.
7Dellian M,Witwer BP,Salehi HA,et al.Quantitation and physiological characterization of angiogenic vessels in mice:effect of basic fibroblast growth factor,vascular endothelial growth factor/vascular permeability factor,and host microenvironment[J].Am J Pathol,1996,149(1):59-71.
8Rajagopalan S,Olin J,Deitcher S,et al.Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients:phase I dose-escalation experience[J].Circulation,2007,115(10):1234-1243.
9Carmeliet P.VEGF gene therapy:stimulating angiogenesis or angioma-genesis[J] ? Nat Med,2000,6(10):1102-1103.
10Marui A,Tabata Y,Kojima S,et al.A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel:an initial report of the phase I-IIa study[J].Circ J,2007,71(8):1181-1186.
1Ramdass M J, Harnarayan P, Mooteeram N, et al.Patterns of arteriosclerotic lesions of the lower extremity in a west Indian population based on angiographic findings and ethnicity[J].Ann R Coil Surg Engl, 2014, 96 ( 2 ) : 121-126.
2Tsai T T, Rehring T F, Rogers R Kein, et al.The contemporary safety and effeetiveness of lower extremity bypass surgeryand peripheral endovascular interventions in the treatment of symptomatic peripheral arterial disease[J].Circulation, 2015, 132 (21) : 1999-2011.
3Lo R C, Bensley R P, Dahlberg S E, et al.Presentation, treatment, and outcome differences between men and women undergoing revascularization or amputation for lower extremity peripheral arterial disease[J].J Vasc Surg, 2014, 59 ( 2 ) : 409- 418.
